Cargando…
Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs)
Over 75% of depressed patients suffer from painful symptoms predicting a greater severity and a less favorable outcome of depression. Imaging, anatomical and functional studies have demonstrated the existence of common brain structures, neuronal pathways and neurotransmitters in depression and pain....
Autores principales: | Hache, Guillaume, Coudore, François, Gardier, Alain M., Guiard, Bruno P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053958/ http://dx.doi.org/10.3390/ph4020285 |
Ejemplares similares
-
Triple Reuptake Inhibitors: The Next Generation of Antidepressants
por: Marks, David M, et al.
Publicado: (2008) -
SNORD90 induces glutamatergic signaling following treatment with monoaminergic antidepressants
por: Lin, Rixing, et al.
Publicado: (2023) -
Antidepressant-like Effects of LPM580153, A Novel Potent Triple Reuptake Inhibitor
por: Zhang, Fangxi, et al.
Publicado: (2016) -
Blue Again: Perturbational Effects of Antidepressants Suggest Monoaminergic Homeostasis in Major Depression
por: Andrews, Paul W., et al.
Publicado: (2011) -
The monoaminergic pathways and inhibition of monoamine transporters interfere with the antidepressive-like behavior of ketamine
por: Viana, Glauce Socorro de Barros, et al.
Publicado: (2017)